

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Lifeloc Technologies, Inc

Form: 8-K

Date Filed: 2018-11-19

Corporate Issuer CIK: 1493137

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2018

LIFELOC TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Colorado

(State or other jurisdiction of
incorporation)

000-54319

(Commission File Number)

84-1053680

(IRS Employer Identification Number)

12441 West 49th Ave., Unit 4
Wheat Ridge, CO

(Address of Principal Executive Offices)

80033

(Zip Code)

(303) 431-9500

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2018, Lifeloc Technologies, Inc. (the "Company") issued a press release announcing its operating results for the third quarter of 2018. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Form 8-K, including the exhibit attached hereto, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
<u>99.1</u>	<u>Press Release, dated November 13, 2018, issued by the Company.</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 19, 2018

LIFELOC TECHNOLOGIES, INC.

By: /s/ Vern D. Kornelsen
Chief Financial Officer and Secretary

Lifeloc Reports Third Quarter 2018 Results

WHEAT RIDGE, Colo., November 13, 2018 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the third quarter ended September 30, 2018.

Third Quarter Financial Highlights

We posted quarterly net revenue of \$2.06 million resulting in quarterly net income after taxes of \$58 thousand, or \$0.02 per diluted share. These results compare to net revenue of \$2.00 million for quarterly net income of \$190, or \$0.00 per diluted share, in the second quarter of 2017. Revenue for the quarter grew 3% versus the third quarter last year and year to date revenue grew for the first nine months of 2018 6% versus the first nine months last year.

This quarter was the fourth consecutive quarter with year over year growth as our distribution channels improve. Gross margin on net revenue improved in the current quarter to 46% versus 44% in the same quarter last year primarily due modestly better volume and a better product mix.

Strategic Highlights

Our vision is that Lifeloc becomes the world's leading company in real-time alcohol and drug abuse detection and monitoring. To that effect, we continue to invest aggressively in research and development. This investment amounted to 13% of revenue for the first 9 months of the year. Lifeloc has focused product development on three specific fronts.

- We will continue to push the bounds on our core portable breathalyzer business as we build a completely new breathalyzer platform with features that customers have demanded. Keeping our core business at the leading technical edge is critical as the core business allows us to fund our growth opportunities. This new breathalyzer platform is expected to begin limited production before the end of this year, with full scale production in the first quarter 2019.
- We will build our alcohol monitoring business utilizing the Real-time Alcohol Detection and Recognition or R.A.D.A.R.® device product line acquired last year. R.A.D.A.R. devices are alcohol monitoring units with biometrics which can be used as a tool to supervise offenders as an alternative to incarceration. The upgraded R.A.D.A.R. device – with a more robust design and better communications – is expected to relaunch in the first quarter of 2019.
- The marijuana breathalyzer took a step closer to realization with the detection of delta-9-THC (the psychoactive agent) captured from a vapor sample. The ability of our technology to detect delta-9-THC down to a concentration of 5 nanograms per milliliter has been demonstrated in our laboratories. Detection is accomplished through the SpinDx technology, licensed exclusively by Lifeloc Technologies for drugs of abuse from Sandia National Laboratory. More work is needed to convert this technology into a simple-to-operate device suitable for roadside testing. The next step is human testing of the collection and detection mechanism.

“We are working hard to improve the business through investment both in infrastructure and new product development,” commented Dr. Wayne Willkomm, President and CEO. “We are nearing the end of the investment cycle in infrastructure with the winding down of implementation expenses of this year’s new ERP (Enterprise Resource Planning) system. Likewise, we expect to start to realize benefits from the heavy product investments of the last few years.”

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

R.A.D.A.R.® is a registered trademark of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Sarah Foley
Lifeloc Technologies, Inc.
<http://www.lifeloc.com>
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets

ASSETS

	September 30, 2018 (Unaudited)	December 31, 2017
CURRENT ASSETS:		
Cash	\$ 2,657,328	\$ 2,669,455
Accounts receivable, net	724,221	593,326
Inventories, net	1,354,768	1,175,103
Income taxes receivable	53,089	121,401
Prepaid expenses and other	85,486	21,804
Total current assets	4,874,892	4,581,089
PROPERTY AND EQUIPMENT, at cost:		
Land	317,932	317,932
Building	1,928,795	1,928,795
Real-time Alcohol Detection And Recognition equipment and software	569,448	569,448
Production equipment and software	783,490	556,025
Training courses	432,375	432,375
Office equipment and software	270,241	204,282
Sales and marketing equipment	273,433	216,330
Research and development equipment and software	159,810	131,770
Less accumulated depreciation	(1,658,104)	(1,349,499)
Total property and equipment, net	3,077,420	3,007,458
OTHER ASSETS:		
Patents, net	174,045	177,244
Deposits and other	5,144	259,037
Deferred taxes	77,782	66,531
Total other assets	256,971	502,812
Total assets	\$ 8,209,283	\$ 8,091,359

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:		
Accounts payable	\$ 315,219	\$ 297,096
Term loan payable, current portion	42,757	42,101
Customer deposits	15,941	48,763
Accrued expenses	272,085	264,290
Deferred revenue, current portion	45,027	53,137
Reserve for warranty expense	41,000	40,000
Total current liabilities	732,029	745,387
TERM LOAN PAYABLE, net of current portion and debt issuance costs	1,380,201	1,410,185
DEFERRED REVENUE, net of current portion	10,354	9,683
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY:		
Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding	4,593,279	4,580,177
Retained earnings	1,493,420	1,345,927
Total stockholders' equity	6,086,699	5,926,104
Total liabilities and stockholders' equity	\$ 8,209,283	\$ 8,091,359

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

	Three Months Ended September 30,	
	2018	2017
REVENUES:		
Product sales	\$ 1,985,520	\$ 1,944,734
Royalties	46,417	43,785
Rental income	23,822	12,160
Total	<u>2,055,759</u>	<u>2,000,679</u>
COST OF SALES	<u>1,111,067</u>	<u>1,118,203</u>
GROSS PROFIT	944,692	882,476
OPERATING EXPENSES:		
Research and development	249,092	242,005
Sales and marketing	331,505	367,101
General and administrative	271,172	268,667
Total	<u>851,769</u>	<u>877,773</u>
OPERATING INCOME	92,923	4,703
OTHER INCOME (EXPENSE):		
Interest income	7,676	1,036
Interest expense	(14,957)	(15,261)
Total	<u>(7,281)</u>	<u>(14,225)</u>
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES	85,642	(9,522)
(PROVISION FOR) BENEFIT FROM FEDERAL AND STATE INCOME TAXES	<u>(27,478)</u>	<u>9,712</u>
NET INCOME	<u>\$ 58,164</u>	<u>\$ 190</u>
NET INCOME PER SHARE, BASIC	<u>\$ 0.02</u>	<u>\$ -</u>
NET INCOME PER SHARE, DILUTED	<u>\$ 0.02</u>	<u>\$ -</u>
WEIGHTED AVERAGE SHARES, BASIC	<u>2,454,116</u>	<u>2,454,116</u>
WEIGHTED AVERAGE SHARES, DILUTED	<u>2,504,116</u>	<u>2,511,925</u>

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

	Nine Months Ended September 30,	
	2018	2017
REVENUES:		
Product sales	\$ 6,121,553	\$ 5,706,328
Royalties	207,840	268,127
Rental income	57,524	57,075
Total	<u>6,386,917</u>	<u>6,031,530</u>
COST OF SALES	<u>3,446,592</u>	<u>3,171,449</u>
GROSS PROFIT	2,940,325	2,860,081
OPERATING EXPENSES:		
Research and development	840,647	690,198
Sales and marketing	997,563	1,074,219
General and administrative	864,629	858,987
Total	<u>2,702,839</u>	<u>2,623,404</u>
OPERATING INCOME	237,486	236,677
OTHER INCOME (EXPENSE):		
Interest income	14,113	4,682
Interest expense	(47,045)	(45,572)
Total	<u>(32,932)</u>	<u>(40,890)</u>
NET INCOME BEFORE PROVISION FOR TAXES	204,554	195,787
PROVISION FOR FEDERAL AND STATE INCOME TAXES	<u>(57,061)</u>	<u>(49,736)</u>
NET INCOME	<u>\$ 147,493</u>	<u>\$ 146,051</u>
NET INCOME PER SHARE, BASIC	<u>\$ 0.06</u>	<u>\$ 0.06</u>
NET INCOME PER SHARE, DILUTED	<u>\$ 0.06</u>	<u>\$ 0.06</u>
WEIGHTED AVERAGE SHARES, BASIC	<u>2,454,116</u>	<u>2,454,116</u>
WEIGHTED AVERAGE SHARES, DILUTED	<u>2,504,116</u>	<u>2,520,414</u>

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)

	Nine Months Ended September 30,	
	2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 147,493	\$ 146,051
Adjustments to reconcile net income to net cash provided from (used in) operating activities-		
Depreciation and amortization	320,983	225,310
Provision for inventory obsolescence, net change	42,500	37,500
Deferred taxes, net change	(11,251)	12,836
Reserve for warranty expense, net change	1,000	1,000
Stock based compensation expense related to stock options	13,102	18,494
Changes in operating assets and liabilities-		
Accounts receivable	(130,895)	(228,666)
Inventories	(222,165)	(414,648)
Income taxes receivable	68,312	16,134
Prepaid expenses and other	(63,682)	(204)
Deposits and other	253,893	(145,010)
Accounts payable	18,123	96,348
Customer deposits	(32,822)	14,423
Accrued expenses	7,795	20,889
Deferred revenue	(7,439)	(6,861)
Net cash provided from (used in) operating activities	<u>404,947</u>	<u>(206,404)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	(378,567)	(139,736)
Cash paid for software acquired in asset acquisition	-	(396,948)
Cash paid for equipment acquired in asset acquisition	-	(351,250)
Reclassification of equipment and software acquired in asset acquisition as inventory	-	178,750
Cash paid for patents and patent applications acquired in asset acquisition	-	(100,000)
Patent filing expense	(6,648)	(17,217)
Net cash (used in) investing activities	<u>(385,215)</u>	<u>(826,401)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Principal payments made on term loan	(31,859)	(30,335)
Net cash (used in) financing activities	<u>(31,859)</u>	<u>(30,335)</u>
NET (DECREASE) IN CASH	(12,127)	(1,063,140)
CASH, BEGINNING OF PERIOD	<u>2,669,455</u>	<u>3,772,064</u>
CASH, END OF PERIOD	<u>2,657,328</u>	<u>\$ 2,708,924</u>
SUPPLEMENTAL INFORMATION:		
Cash paid for interest	<u>\$ 44,270</u>	<u>\$ 30,040</u>
Cash paid for income tax	<u>\$ -</u>	<u>\$ 13,844</u>